Speaker information is updated as they are confirmed, please bookmark this site for later reference.
Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the Genomes2People Research Program in translational genomics and health outcomes at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School.
Dr. Green is accelerating the implementation of genomics into medicine by conducting rigorously designed research on medical, behavioral and economic outcomes of genomic testing. He leads the first randomized trials of clinical genome sequencing in adults (the MedSeq Project) and newborns (the BabySeq Project), and was recently awarded the first research project on clinical sequencing of personnel in the US Armed Forces.
He has been continuously funded by NIH for over 26 years and has published over 300 scientific papers. In 2014, he won the Coriell Prize for Scientific Achievement in Personalized Medicine. His work has been repeatedly highlighted on NBC Nightly News, the Today Show, CNBC, the New York Times, the Wall Street Journal, Time Magazine, New Scientist, FastCompany and Buzzfeed.
He has forged research collaborations with Genomics England, Illumina, 23andMe and Google; advises a number of biotechnology and genomics companies, and has co-founded an investor-backed telemedicine start-up company, Genome Medical, Inc. He has been invited to speak at the World Science Festival, Forbes Healthcare Summit, Exponential Medicine, JP Morgan Healthcare and South By Southwest.
Dr. Green graduated from Amherst College and the University of Virginia School of Medicine, and earned a Masters of Public Health in epidemiology from Emory University School of Public Health. He obtained specialty training at Harvard Medical School residencies and fellowships, and is board certified in both neurology and medical genetics.
Dr. William A. Gahl earned his B.S. degree in biology from the Massachusetts Institute of Technology in 1972 and his M.D. and Ph.D. from the University of Wisconsin. He served as pediatric resident and chief resident at the University of Wisconsin hospitals from 1976-80. In 1984, he completed clinical genetics and clinical biochemical genetics fellowships at the NIH's Inter-Institute Medical Genetics Training Program, which he directed from 1989 to 1994. Dr. Gahl elucidated the basic defects in cystinosis and Salla disease and helped bring cysteamine to new drug approval by the Food and Drug Administration as the treatment for cystinosis. His group described the natural history of Lowe syndrome, alkaptonuria, autosomal recessive polycystic kidney disease, Chediak-Higashi disease, GNE myopathy, and Hermansky-Pudlak syndrome (HPS), and his lab discovered the genetic bases of gray platelet syndrome, Hartnup disease, arterial calcification due to deficiency of CD73, 3-methylglutaconic aciduria type III, 3 types of HPS, and neutropenia due to VPS45 deficiency.
Dr. Gahl has published more than 380 peer-reviewed papers, trained over 40 biochemical geneticists, and established American Board of Medical Specialties certification for medical biochemical genetics. He served on the board of directors of the American Board of Medical Genetics and American Society of Human Genetics, as President of the Society for Inherited Metabolic Disorders, and was elected to the American Society for Clinical Investigation and the Association of American Physicians. His accolades include the Dr. Nathan Davis Award for Outstanding Government Service from the American Medical Association, the Service to America Medal in Science and the Environment, the RareVoice Award for a Government Agency Leader, and numerous other awards.